Jasper Therapeutics, Inc.
JSPR
$4.87
$0.020.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.39% | 1.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.77% | 27.13% | |||
| Operating Income | 13.77% | -27.13% | |||
| Income Before Tax | 12.66% | -30.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.66% | -30.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.66% | -30.50% | |||
| EBIT | 13.77% | -27.13% | |||
| EBITDA | 14.05% | -29.42% | |||
| EPS Basic | 12.74% | -30.43% | |||
| Normalized Basic EPS | 12.75% | -30.30% | |||
| EPS Diluted | 12.74% | -30.43% | |||
| Normalized Diluted EPS | 12.75% | -30.30% | |||
| Average Basic Shares Outstanding | 0.09% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||